UPMC Children's Hospital Pittsburgh
Pittsburgh, Pennsylvania, 15235, United States
NCT Number: NCT05634226
This is a pilot study using a novel, minimal risk, portable, hands-free oral-positive pressure device (oPEP) in patients with Fontan palliation that will examine whether using this device in both the acute and chronic phase will alter Fontan hemodynamics and create pulsatility in the Fontan circuit and thereby increasing cardiac output. This device is easy to use and poses no significant risk to human subjects. The investigators will measure this through echocardiographic measures including pulsatility in different aspects of the Fontan circuit including IVC, hepatic veins, the Fontan conduit, and pulmonary arteries and aortic blood flow measurements. After demonstration of how to use the device appropriately, the investigators will have patients use the device after their clinical echocardiogram for their clinic appointment. The investigators will ask them to use the device at home 3-4 times a day for 10-15 mins and have them return in approximately 4 weeks to have another echocardiogram done with the same measurements.
Looking for future studies?
Notify Me8 year and older
All sexes
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15235, United States
The aortic VTI secondary outcome was inadvertently left out of the initial registration and is now reported
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is a pilot study using a novel, minimal risk, portable, hands-free oral-positive pressure device (oPEP) in patients with Fontan palliation that will examine whether using this device in both the acute and chronic phase will alter Fontan hemodynamics and create pulsatility in the Fontan circuit and thereby increasing cardiac output. This device is easy to use and poses no significant risk to human subjects. We will measure this through echocardiographic measures including pulsatility in different aspects of the Fontan circuit including IVC, hepatic veins, the Fontan conduit, and pulmonary arteries and aortic blood flow measurements. After demonstration of how to use the device appropriately, we will have patients use the device after their clinical echocardiogram for their clinic appointment. We will ask them to use the device at home 3-4 times a day for 10-15 mins and have them return in approximately 4 weeks to have another echocardiogram done with the same measurements.
Time frame: The change is between enrollment echocardiogram and echocardiogram after 4 week use of the device
This will be measured by echocardiogram using Doppler evaluation of the pulmonary artery
The Pulmonary Artery Pulsatility Index (PAPI) is calculated using Doppler-derived pulmonary artery velocities:
PAPI= (Systolic Velocity - Diastolic Velocity) /Mean Velocity
Time frame: Baseline, 4 weeks
This was measured by echocardiography
Aortic Valve Velocity Time Integral (VTI) Definition: Aortic VTI is a key echocardiographic measurement reflecting stroke distance and cardiac output.
Measurement:
Obtained using pulsed-wave Doppler at the left ventricular outflow tract (LVOT) just below the aortic valve.
The VTI is measured by tracing the Doppler envelope of the LVOT flow during systole.
Clinical Importance:
Stroke Volume Calculation:
Stroke Volume = LVOT VTI × LVOT Area
Tarek Alsaied
Other
Oral Positive Pressure Device (oPEP) Effect on Flow Pulsatility in the Fontan Circuit
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04901975
Cardiovascular Abnormalities, Cardiovascular Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04195451
Cardiovascular Abnormalities, Cardiovascular Diseases
Palo Alto, California, United States
View Trial DetailsNCT05034354
Biventricular Congestive Heart Failure, Cardiovascular Abnormalities
Edmonton, Alberta, Canada
View Trial DetailsNCT02975999
Cardiovascular Abnormalities, Cardiovascular Diseases
Oak Lawn, Illinois, United States
View Trial Details